[go: up one dir, main page]

PE20030761A1 - Derivados del 7-amino-benzotiazol - Google Patents

Derivados del 7-amino-benzotiazol

Info

Publication number
PE20030761A1
PE20030761A1 PE2002001192A PE2002001192A PE20030761A1 PE 20030761 A1 PE20030761 A1 PE 20030761A1 PE 2002001192 A PE2002001192 A PE 2002001192A PE 2002001192 A PE2002001192 A PE 2002001192A PE 20030761 A1 PE20030761 A1 PE 20030761A1
Authority
PE
Peru
Prior art keywords
alkyl
amino
benzothiazol
benzamide
methoxy
Prior art date
Application number
PE2002001192A
Other languages
English (en)
Inventor
Alexander Flohr
Claus Riemer
Roger David Norcross
Roland Jakob-Roetne
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20030761A1 publication Critical patent/PE20030761A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I DONDE R1 Y R2 SON H, ALQUILO, CICLOALQUILO C1-C6, TETRAHIDROPIRAN-2,3 O 4-ILO CON ALQUILO, -(CH2)n-O-ALQUILO, ENTRE OTROS; R1 Y R2 JUNTOS A N FORMAN EL ANILLO 2-OXA-5-AZA-BICICLO[2.2.1]HEPT-5-ILO O UN ANILLO DE AZETIDINILO; R3 ES ALCOXILO, FENILO CON HALOGENO, -(CH2)n-HALOGENO, PIRIDINILO CON ALQUILO, HALO; n ES 1-2; R' Y R'' SON H, ALQUILO Y JUNTO CON N FORMAN UN GRUPO AZETIDINILO, PIRROLIDINILO, PIPERIDINILO. SON COMPUESTOS PREFERIDOS N-{4-METOXI-7-[(2-METOXI-ETIL)-METIL-AMINO]-BENZOTIAZOL-2-IL}-BENZAMIDA, 4-FLUOR-N-{4-METOXI-7-[(2-METOXI-ETIL)-METIL-AMINO]-BENZOTIAZOL-2-IL}-BENZAMIDA, N-{7-[ACETIL-(4-METIL-BENCIL)-AMINO]-4-METOXI-BENZOTIAZOL-2-IL}-BENZAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCESO PARA LA PREPARACION Y COMPUESTOS INTERMEDIOS. LOS COMPUESTOS MENCIONADOS SE RELACIONAN CON EL RECEPTOR A2A DE LA ADENOSINA Y SON UTILES PARA EL TRATAMIENTO DE ALZHEIMER, PARKINSON
PE2002001192A 2001-12-12 2002-12-11 Derivados del 7-amino-benzotiazol PE20030761A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01129272 2001-12-12

Publications (1)

Publication Number Publication Date
PE20030761A1 true PE20030761A1 (es) 2003-09-05

Family

ID=8179486

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001192A PE20030761A1 (es) 2001-12-12 2002-12-11 Derivados del 7-amino-benzotiazol

Country Status (18)

Country Link
US (1) US6713499B2 (es)
EP (1) EP1456188A1 (es)
JP (1) JP4244189B2 (es)
KR (1) KR100581705B1 (es)
CN (1) CN1305862C (es)
AR (1) AR037767A1 (es)
AU (1) AU2002360960B8 (es)
BR (1) BR0214884A (es)
CA (1) CA2469884A1 (es)
GT (1) GT200200269A (es)
MX (1) MXPA04005633A (es)
PA (1) PA8561001A1 (es)
PE (1) PE20030761A1 (es)
PL (1) PL373953A1 (es)
RU (1) RU2299203C2 (es)
TW (1) TW200409763A (es)
UY (1) UY27580A1 (es)
WO (1) WO2003053946A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734179B2 (en) * 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
CN1791405A (zh) * 2003-05-21 2006-06-21 弗·哈夫曼-拉罗切有限公司 苯并噻唑衍生物及其在治疗涉及腺苷a 2a受体的疾病中的应用
AU2004274154A1 (en) * 2003-09-19 2005-03-31 F. Hoffmann-La Roche Ag Thiazolopyridine derivatives as adenosine receptor ligands
TW200524887A (en) * 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
WO2005044793A2 (en) * 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
KR100834179B1 (ko) * 2004-05-24 2008-05-30 에프. 호프만-라 로슈 아게 4-하이드록시-4-메틸-피페리딘-1-카복실산(4-메톡시-7-모폴린-4-일-벤조티아졸-2-일)-아마이드
WO2005116026A1 (en) 2004-05-24 2005-12-08 F. Hoffmann-La Roche Ag 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
BRPI0513510A (pt) * 2004-07-22 2008-05-06 Hoffmann La Roche benzotiazóis substituìdos
RU2382782C2 (ru) 2004-07-22 2010-02-27 Ф. Хоффманн-Ля Рош Аг Производные бензотиазола
EP1794157B1 (en) 2004-09-22 2014-02-26 H. Lundbeck A/S 2-acylaminothiazole derivatives
US8604055B2 (en) * 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006073973A2 (en) * 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
AU2006226669B2 (en) 2005-03-23 2011-12-08 F. Hoffmann-La Roche Ag Acetylenyl-pyrazolo-pvrimidine derivatives as mGluR2 antagonists
US7674912B2 (en) 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
AU2006298829B2 (en) 2005-09-27 2011-03-03 F. Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mGluR2 antagonists
BRPI0712516A2 (pt) 2006-05-18 2016-08-23 Hoffmann La Roche compostos, composições farmacêuticas, antagonista receptor de a2b, método para uso terapêutico e/ou tratamento profilático e uso de antagonista receptor de a2b
US8168785B2 (en) * 2009-06-17 2012-05-01 Biotie Therapies, Inc. Benzothiazole derivatives
RU2448100C1 (ru) * 2010-09-24 2012-04-20 Татьяна Николаевна Иванова Производные 2-аминобензотиазола, обладающие противогипоксической активностью, и способ их использования
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
MX2014001849A (es) 2011-08-18 2014-10-24 Reddys Lab Ltd Dr Compuestos de amina heterociclicos sustituidos como inhibidores de proteina de transferencia de ester colesterilo (cetp).
EP2760864B1 (en) 2011-09-27 2018-01-24 Dr. Reddy's Laboratories Ltd. 5-BENZYLAMINOMETHYL-6-AMINOPYRAZOLO[3,4-b]PYRIDINE DERIVATIVES AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS USEFUL FOR THE TREATMENT OF ATHEROSCLEROSIS
WO2017136375A1 (en) * 2016-02-05 2017-08-10 Concert Pharmaceuticals, Inc. Deuterated tozadenant
WO2019025099A1 (en) * 2017-08-01 2019-02-07 Merck Patent Gmbh THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
DE102019110904B4 (de) 2019-04-26 2022-01-20 Helmholtz-Zentrum Dresden - Rossendorf E. V. N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2041216C1 (ru) * 1991-04-04 1995-08-09 Эйсай Ко., Лтд. Производное бензотиазола или его фармакологически приемлемая соль
WO2000018767A2 (en) 1998-09-30 2000-04-06 Neurogen Corporation 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
KR100526487B1 (ko) 2000-06-21 2005-11-08 에프. 호프만-라 로슈 아게 벤조티아졸 유도체

Also Published As

Publication number Publication date
CA2469884A1 (en) 2003-07-03
MXPA04005633A (es) 2004-12-06
PL373953A1 (en) 2005-09-19
UY27580A1 (es) 2003-06-30
WO2003053946A1 (en) 2003-07-03
JP2005526706A (ja) 2005-09-08
CN1604897A (zh) 2005-04-06
RU2004121688A (ru) 2005-05-27
RU2299203C2 (ru) 2007-05-20
US6713499B2 (en) 2004-03-30
BR0214884A (pt) 2004-11-23
GT200200269A (es) 2003-07-30
KR100581705B1 (ko) 2006-05-22
JP4244189B2 (ja) 2009-03-25
PA8561001A1 (es) 2003-12-10
US20030153566A1 (en) 2003-08-14
AU2002360960B2 (en) 2008-03-06
CN1305862C (zh) 2007-03-21
EP1456188A1 (en) 2004-09-15
TW200409763A (en) 2004-06-16
AR037767A1 (es) 2004-12-01
AU2002360960A1 (en) 2003-07-09
AU2002360960B8 (en) 2008-04-10
KR20040073472A (ko) 2004-08-19

Similar Documents

Publication Publication Date Title
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
DK1382604T3 (da) Quinolinderivater med en azolylgruppe og quinazolinderivater
PE20040189A1 (es) Pirimidina y piridina biciclicos como inhibidores de p38 quinasa
YU108791A (sh) Pirazolopirimidinon antianginalna jedinjenja
ES2167371T3 (es) Derivados de 1h-3-aril-pirrolidin-2,4-diona espirociclicos substituidos.
NO20051694L (no) Heterosykliske forbindelser
PE20011287A1 (es) Derivados de imidazopirimidina y derivados de triazolopirimidina
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
NO983970L (no) Tricykliske forbindelser, deres fremstilling og anvendelse
ES2162857T3 (es) Derivados fenilicos trisustituidos utilizados como inhibidores de fosfodiesterasa.
AR035111A1 (es) Procedimiento para preparar un compuesto de pirimidinona
PE20030759A1 (es) Uso de ureas de benzotiazoles
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
NZ528997A (en) Sulfonamides
AR029400A1 (es) Derivados de isoxazolcarboxamida, un metodo para su preparacion y una composicion farmaceutica que los comprende
EA200101224A1 (ru) Производные пурина, способ их получения и содержащие их фармацевтические композиции
NO20054095L (no) Pyridyloksymetyl og benzioksazolazabicyklisk derivater
ATE243209T1 (de) Tetrahydro gamma-carboline
AR039122A1 (es) Derivados de ftalimido como inhibidores de monoamino oxidasa b
FI884077A0 (fi) Amidfoereningar, foerfarande foer deras framstaellning och dessa innehaollande kompositioner foer aktivering av gastrisk motorfunktion.
AR037211A1 (es) Derivados de heteroarilo como ligandos superiores para el receptor de nociceptina orl-1
AR034206A1 (es) Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
PE20010649A1 (es) Derivados de antranilamida de piperidinas 1,4-di-sustituidas como antagonistas muscarinicos
FI893901A0 (fi) Menetelmä tetrasyklisten masennuslääkkeiden valmistamiseksi

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed